MOTS-c Cycle: Duration, and Where It Comes From
Trace any stated cycle length backwards far enough and it stops at a forum post rather than at a study.
Every stated MOTS-c cycle you will find online is presented as if it came from somewhere. Follow one back and it does not. There is no published human duration study for this compound, no approved labelling anywhere in the world, and no completed trial that fixed a treatment period and reported on it. The lengths in circulation are conventions, and conventions have origins worth tracing.
Where the order actually gets placed
Ascension Peptides, MOTS-c
US-based and third-party tested. Enter the code on the payment step and the vial halves before you confirm.
Buying 3, 5 or 10 vials takes 3%, 5% or 10% off the list price. Free shipping starts at $250, which one discounted vial does not reach.
- Two batch certificates per lot
- Shipping free over $250
- Out the door same day if you order before 2pm CST
Everything here is research material for laboratory use, not for human consumption. Affiliate links, so we may earn a commission at no cost to you. Prices last checked August 19, 2026.
Tracing a stated MOTS-c cycle back to its source
Do this with any specific schedule you encounter and the trail is short.
You start with a number on a page. Usually a count of weeks, sometimes with an off period attached. The page presents it in the register of established practice, without a citation, because a citation would have to point somewhere.
You look for the source. Most pages of this kind cite nothing. Those that do cite something point to another page of the same kind, which points to a third. The chain terminates in a forum post, a vendor's product description, or a sentence that begins "commonly used protocols suggest", which is a sentence with no subject.
You look for the study instead. What exists in the published record is animal and cell work, and nothing at all in people.
There is one thing that survives a careless version of this search, and running the same trace on it is the most useful part of the exercise. ClinicalTrials.gov holds a record, NCT07505745, which is Phase 2, lists 120 adults with prediabetes and overweight or obesity, and is marked recruiting. Trace it one step further, to the lead sponsor field, and it names Hudson Biotech, which holds eight such records first posted between February and April 2026, all recruiting, all naming a single hospital, covering MOTS-c alongside BPC-157, Melanotan II, GHK-Cu, retatrutide, tesamorelin, tirzepatide and TB-500. The summary of the TB-500 entry says outright that it is a fictional example of a ClinicalTrials.gov-style record.
So the trace ends the way the cycle-length trace ended, one step further along than most readers go: at something presented as a source that turns out not to be one. Neither yields a duration a reader could follow.
That is the whole trace, and it takes about ten minutes to run yourself on any compound sold this way.
The three things people are actually quoting
Cycle numbers do come from somewhere, just not from where they imply.
The first source is animal study design. A rodent experiment specifies a treatment period, because it has to. Someone reads that period, converts it loosely, and publishes it as a human schedule. What gets left behind is that the period in a mouse study is bounded by an induced condition at one end and tissue collection at the other, neither of which happens to a person.
The second source is habit carried over from anabolic steroid use, where cycling on and off has a specific rationale involving suppression of the body's own hormone production. That rationale is about those compounds. Whether anything equivalent applies to a mitochondrial derived peptide has not been established in published human work, and the practice was inherited rather than derived.
The third source is the vial. Research chemical peptides are sold in a fixed quantity per vial, and a schedule that consumes a vial in a tidy number of weeks is easier to sell and easier to repeat than one that does not. Nobody has to be dishonest for commercial packaging to shape what looks like a protocol.
Questions that interrupt at about this point
Is there a standard MOTS-c cycle length?expand_more
Do the mouse studies imply a duration?expand_more
Why do so many pages agree on similar numbers?expand_more
Does the ClinicalTrials.gov entry give a schedule to follow?expand_more
What an animal treatment period actually is
It helps to see the shape of one, because the shape is what does not transfer.
A rodent metabolic study begins by establishing the condition being studied, through diet or through a genetic trait, and confirming it by measurement. That is a fixed starting line, known to the day.
Treatment then runs for a period chosen before the experiment starts, for reasons specific to that experiment: how long the model takes to respond, what the funding allowed, what the comparison group is doing, and what earlier work in the same laboratory used.
The period ends at a scheduled point, and what happens at that point is measurement, frequently including measurements that require the tissue itself. In mice, this design has produced the metabolic findings that this compound is known for.
None of the three anchors survives translation. A person has no known starting line, no reason to prefer one length over another, and no endpoint measurement to schedule the finish around.
The step that is always missing: how you would know it worked
Set the sourcing problem aside for a moment and look at the practical shape of a cycle.
A schedule is a plan to do something for a fixed period and then evaluate. The evaluation is the point. Without it, a cycle is just an interval, and the interval carries no information about whether continuing, stopping or changing anything would be sensible.
Now ask what the evaluation would consist of for this compound. The endpoint the animal work concentrated on is insulin sensitivity. That is inferred from blood measurements taken under controlled conditions. It is not a sensation, it does not announce itself, and a person following a schedule at home has no reading of it on the day they started or on the day they stop.
So the plan ends with a blank. The person reaches the end of week whatever, and the only available inputs are how they feel and how they look, neither of which is the thing the research measured, and both of which move for a dozen unrelated reasons across any period long enough to be called a cycle.
That is why a stated duration can look so specific and mean so little. Precision at the front of a plan is worth nothing if the back of the plan has no measurement attached. A schedule that ends in a subjective impression is not a protocol with a defined length. It is an interval with a guess at the end of it.
What the circulating cycle claims rest on
| Element of a stated cycle | Where it is presented as coming from | What actually supports it | Organism |
|---|---|---|---|
| A number of weeks on | Research | No published human duration study | Not applicable |
| An amount per administration | Converted animal work | Animal dosing set per kilogram of body weight | Mouse |
| A break between runs | Common practice | Rationale imported from a different compound class | Not applicable |
| Repeating the cycle | Convention | No published repeat exposure data in people | Not applicable |
| An expected point where effects appear | Personal accounts | No published human efficacy results | Human, uncontrolled |
| Stopping criteria | Rarely stated at all | No published human safety timeline | Not applicable |
Read the third column on its own and the pattern is clear. Every element that sounds precise is supported by something other than a study of that element.
The honest position, and what would change it
No human trial of this compound has been run. That is the fact that decides what can be said about duration today, and the registry entry that appears to say otherwise does not soften it, because a registration is a submission that was accepted rather than a study anyone reviewed.
An evidence based cycle length becomes possible when a completed human trial that fixed a treatment period in advance publishes results across that period. Then a duration would have a source, a population it applies to, and a stated outcome it was measured against. None of those three exist now.
Meanwhile there is a separate problem sitting underneath the schedule question. This compound is sold as a research chemical, with no marketing authorisation from the FDA, the EMA, the MHRA or any other regulator. Contents are not verified by anyone with an obligation to be right. A cycle is a plan for consuming a specific substance over a specific period, and if the substance is unconfirmed then the precision of the plan is decorative.